CORONARY INTERVENTIONS

Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

EuroIntervention 2016;12:e160-e166 published online e-edition June 2016. DOI: 10.4244/EIJ-D-15-00371

Michael Haude1*, MD, PhD; Raimund Erbel2, MD, PhD; Paul Erne3, MD, PhD; Stefan Verheye4, MD; Hubertus Degen1, MD; Paul Vermeersch4, MD; Neil Weissman5, MD; Francesco Prati6, MD; Nico Bruining7, MD, PhD; Ron Waksman5, MD; Jacques Koolen8, MD

1. Medical Clinic I, Städtische Kliniken-Neuss, Lukaskrankenhaus GmbH, Neuss, Germany; 2. Department of Cardiology, West German Heart Center Essen, Essen, Germany; 3. Cardiology Department, Luzerner Kantonsspital, Lucerne, Switzerland; 4. Department of Ca

Aims: Bioresorbable scaffolds were designed to overcome the limitations of permanent stents. In the BIOSOLVE-I study we aimed to assess the long-term safety and performance of a drug-elut

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioresorbablecoronary artery diseasedrug-eluting absorbable metal scaffold (dreams)magnesiumpolylactic-co-glycolic acid (plga)scaffold

Coronary interventionsInterventions for valvular diseaseStents and scaffoldsTAVITools, devices and techniques

Share on Facebook Share on Twitter Share on Linkedin